Panel to tackle global data disclosure challenge

Developing a new drug for a global market presents every biopharma company with a complex regulatory challenge. How can you juggle the demands of regulators in Europe and the U.S., as well as other key markets around the globe?

Join us for a unique webinar that will provide expert perspectives on maintaining fruitful relationships with a variety of regulatory agencies, with a special focus on the crucial regulatory communications required on the disclosure of clinical trial data.

We'll cover salient data disclosure requirements from around the world.

Christine Dingivan, M.D., Executive Vice President and Chief Medical Officer, PPD and Patricia Teden, Principal, Teden Consulting will be on hand to provide expert advice on managing global data disclosure challenges. The webinar will take place Thursday, June 24 at 2pm EST.

Click here to register. - George Miller

Suggested Articles

Popular logic says you never switch horses, or CDMOs, in the middle of the stream, but Acacia Pharma had to do that to win an FDA approval.

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

A warning letter says Chinese API maker Yibin Lihao Bio-technical was found lying to the FDA about manufacturing unapproved heparin.